We were hired to articulate this cell therapy’s narrative through messaging, FAQs, milestones and visual storytelling in an industry of stem cell clinic noise and bad actors. Despite competing with vaping death stories and COVID19, two-year awareness is high pending FDA approval. A baseline of zero public awareness turned up attention and placed the company on the map nationwide with news media, KOLs, advocates, analysts and other influencers. GID is on track to become the first cell therapy to treat osteoarthritis of the knee to be FDA approved. Consistent storytelling in paid, earned, shared and owned media campaigns portrays this third pillar of medicine behind surgery and drugs with data in a field lacking evidence-based medicine. GID BIO helps relieve part of the $200BN US healthcare burden of treating OA. Notable (ongoing) results:
- Paid: targeted social media ads drove 63% of intended audiences to the website in six months
- Earned: CBS New Orleans; Denver & San Antonio business journals; Merger Market; OrthoWorld news gave third party credibility and top three strategic partner acquisition interest
- Shared: social media audit, strategy, content; drove 40% (organic) of web traffic (63% with paid ads); 434 KOLs in six months (TOBI, Mayo Clinic, orthopedic surgeons, academia)
- Owned: 12 blogs/SEO for 459 unique web views; nine videos: patient POVs, mechanism of action, leadership; email newsletter campaigns garnered KOLs from Sanofi Genzyme, Fidelity, Conventus, Ambrose, and more; created content for two websites
- Advocacy relations: deep relationships were developed during research and a roundtable with eight nationwide leaders
